![Four big takeaways to wrap up the Paris Air Show [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2023/06/FCAS-scaled-e1685718848105.jpg?#)
![The sights of Paris Air Show, one last time: Day 4 [Photos]](https://breakingdefense.com/wp-content/uploads/sites/3/2025/06/20250617-helenedelacoste-Paris-Air-Show-037-scaled-e1750357690820.jpg?#)
[Articles] Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial
Mitapivat could be a new oral treatment for adults with NTD α-thalassaemia or NTD β-thalassaemia by increasing haemoglobin concentration and improving fatigue.
Mitapivat could be a new oral treatment for adults with NTD α-thalassaemia or NTD β-thalassaemia by increasing haemoglobin concentration and improving fatigue.
